Spectral AI Awarded $31.7 Million of BARDA Funding to Accelerate Development of the DeepView® System
Rhea-AI Summary
Spectral AI (Nasdaq: MDAI) received $31.7 million from BARDA to accelerate feature development of its DeepView® System, an AI burn wound imaging platform. The company will add $9.7 million toward development; BARDA funding supplements $54.9 million previously committed under a contract valued up to $150.0 million. The award is non-dilutive as Spectral AI awaits a determination on market authorization from the U.S. FDA for DeepView.
Positive
- $31.7M in new non-dilutive BARDA funding
- Existing BARDA commitments total $54.9M under a contract up to $150M
- Company committing $9.7M to advance DeepView development
Negative
- DeepView market authorization is pending a U.S. FDA determination
- Project reliant on continued BARDA contracting and future regulatory approval
News Market Reaction – MDAI
In the Mar 19 session, MDAI gained 18.33%, reflecting a significant positive market reaction. Argus tracked a peak move of +75.1% during that session. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous AI Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 10 | CEO appointment | Positive | +0.7% | New CEO named to steer commercialization of DeepView AI burn assessment device. |
| Feb 02 | Awareness campaign | Neutral | -2.9% | Participation in National Burn Awareness Week with safety education and DeepView references. |
| Oct 23 | Equity financing | Negative | -0.9% | Priced $7.6 million offering with shares and warrants to fund DeepView growth. |
| Sep 19 | Industry recognition | Positive | +9.1% | Named to TIME’s World’s Top HealthTech Companies 2025 list for AI wound care. |
| May 29 | Annual meeting results | Neutral | -2.4% | Stockholders approved all proposals with 60.8% of total shares represented. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-tagged news has produced mostly aligned price reactions, with both positive recognition and dilutive financings absorbed without persistent trend change.
Over the past year, AI-tagged news for Spectral AI has focused on leadership changes, financing for DeepView® development, industry recognition, and corporate governance. Notably, a $7.6 million offering in October 2025 funded system expansion, while a new CEO was appointed in February 2026 to support commercialization. Recognition on TIME’s Top HealthTech list in September 2025 coincided with a strong positive move. Today’s BARDA funding update extends this pattern of milestones tied to DeepView’s advancement and commercialization path.
Key Terms
Biomedical Advanced Research and Development Authority regulatory
Food and Drug Administration regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
DALLAS, March 18, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that it has received
This immediate, non-dilutive funding is being advanced in addition to the
“We are pleased to continue our long-standing partnership with BARDA and are grateful for its ongoing support of the DeepView System, a diagnostic tool that empowers physicians to make quick, data-driven decisions that can improve patient outcomes,” said Vincent Capone, Chief Executive Officer of the Company. “Burn wound assessment is crucial in determining next-step treatment for patients, which currently largely relies on the clinical judgement of physicians. This unmet clinical need is dramatically magnified in the event of mass casualty burn incidents, or BMCIs, where the ability to triage burn patients rapidly and properly would be crucial in allocating valuable resources and managing the surgical burden. The DeepView System technology represents a new paradigm in the assessment of burn wounds and can provide meaningful clinical guidance to physicians in their diagnosis and treatment recommendations."
About the DeepView System
The DeepView System is being developed for use in emergency departments, trauma centers and burn centers, for both routine burn care and as a medical countermeasure for use in BMCI. BARDA is part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services. This modification to the BARDA Contract supports the continued development and FDA clearance of the DeepView System for commercial marketing and distribution purposes, a major milestone that enables the technology to assist the U.S. government’s BMCI preparedness efforts, and accelerates a number of other development initiatives in Phase II of the existing contract including further development of total body surface area mapping and analysis.
About BARDA and its Support of the DeepView System
This work supports BARDA’s mission to identify medical countermeasures which help counter the effects of a BMCI and address the current limitations within the United States’ burn care infrastructure. According to the American Burn Association, 1.1 million Americans suffer from burn injuries each year, with 500,000 presenting to emergency departments, and 40,000 requiring hospitalization. In contrast to this demand, only two percent of U.S. hospitals have burn centers, and there are only about 250 burn surgeons in the United States.
This project is being supported in whole or in part with federal funds from the Department of Health and Human Services (DHHS); Administration for Strategic Preparedness and Response; and BARDA, under contract number 75A50123C00049. The findings and conclusions have not been formally disseminated by the DHHS and should not be construed to represent any agency determination or policy.
About Spectral AI
Spectral AI, Inc. is a Dallas-based predictive AI company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving patients with burns. The Company is working to revolutionize the management of wound care by “Seeing the Unknown®” with its DeepView System. The DeepView System is being developed as a predictive diagnostic device to offer clinicians an objective and immediate assessment of a burn wound’s healing potential prior to treatment or other medical intervention. With algorithm-driven results and a goal of exceeding the current standard of care in the future, the DeepView System is expected to provide fast and accurate treatment insight towards value care by improving patient outcomes and reducing healthcare costs. Spectral AI has been named to TIME’s list of World’s Top HealthTech companies 2025. For more information about the DeepView System, visit www.spectral-ai.com.
Forward-Looking Statements
Certain statements made in this release are “forward looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s strategy, plans, objectives, initiatives and financial outlook. When used in this press release, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside Company’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. As such, readers are cautioned not to place undue reliance on any forward-looking statements.
Investors should carefully consider the foregoing factors, and the other risks and uncertainties described in the “Risk Factors” sections of the Company’s filings with the US Securities and Exchange Commission, including the Company’s Registration Statement and the other documents filed by the Company. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements.
| Investors: | |
| The Equity Group | |
| Devin Sullivan | Conor Rodriguez |
| Managing Director | Associate |
| dsullivan@theequitygroup.com | crodriguez@theequitygroup.com |
